Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Cristina AlmenglóMarinela Couselo-SeijasRosa M AgraAlfonso Varela-RománJosé M García-AcuñaMercedes González-PeteiroJosé R González-JuanateySonia EirasEzequiel ÁlvarezPublished in: Journal of molecular medicine (Berlin, Germany) (2021)
The main objective was to compare the meaning of soluble angiotensin-converting enzyme-2 (sACE2) plasma levels modulation on the prognosis of two cohorts of heart failure (HF) and acute coronary syndrome (ACS). We conducted an observational clinical study where sACE2 was measured in two cohorts of HF or ACS (102 patients each), matched by age and gender. The primary endpoint (cardiac death) and the secondary endpoints (non-fatal myocardial infarction or HF readmission) were registered during a 5-year follow-up period. Association with pharmacotherapy was studied, and the effects of cardiovascular drugs on ACE isoforms expression were analysed in human umbilical vein endothelial cells (HUVEC) in vitro. The levels of sACE2 were significantly higher in the HF than ACS cohort. sACE2 was inversely related with the leukocytes number and directly with urea levels. In the ACS cohort, sACE2 was associated with age and glycaemic parameters, but in the HF cohort, the association was with N-terminal pro-B-type natriuretic peptide. The levels of sACE2 were related to long-term prognosis and confirmed as a non-independent predictor in the HF cohort. Soluble ACE2 was higher in patients treated with angiotensin receptors blockers and β-blockers, accordingly with losartan and metoprolol upregulation of ACE1 and ACE2 in HUVECs. Plasma levels of sACE2 were higher in HF than in ACS, independently of age and gender, and were related to long-term cardiac death in the HF cohort. Losartan and metoprolol, but not enalapril, upregulated ACE expression in endothelial cells, accordingly with higher levels of sACE2 in patients using these drugs.
Keyphrases
- angiotensin converting enzyme
- acute coronary syndrome
- angiotensin ii
- acute heart failure
- heart failure
- endothelial cells
- percutaneous coronary intervention
- left ventricular
- antiplatelet therapy
- poor prognosis
- newly diagnosed
- ejection fraction
- prognostic factors
- type diabetes
- mental health
- signaling pathway
- vascular endothelial growth factor